Sun Pharma Q2 Profit Falls 36% Due to Organon Deal Charges
Sun Pharma's Q2 profit dropped by 36% due to exceptional charges related to the Organon deal, despite strong revenue growth and specialty drug sales. The company recorded Rs 346 crore in costs from the Organon transaction. While revenue exceeded estimates, profit declined significantly in this quarter.
Reuters·



